FDA approval puts Wockhardt’s Zaynich in $9 billion antibiotics market

Wockhardts newly approved antibiotic Zaynich has the potential to transform the treatment of drug-resistant infections, according to Mahesh Patel, the scientist behind the drug. Approved by the US FDA for complicated urinary tract infections, Zaynich combines cefepime and zidebactam, using a novel “beta-lactam enhancer” mechanism that blocks two key steps in bacterial cell-wall synthesis, helping it overcome virtually all known resistance mechanisms.

Raccontata daeconomictimes.indiatimes.comthehindubusinessline.commorningstar.comtimesofindia.indiatimes.comhealio.com